15
Nov
J Chem Inf Model. represents a promising target for the development of both cancer and neurodegenerative agents.1C7 Six candidates that target the Hsp90 N-terminus are currently under clinical investigation to assess their efficacy for the treatment of cancer.8,9 Despite these efforts, Hsp90 N-terminal inhibitors induce an undesired, pro-survival heat shock response (HSR), which has impeded their clinical potential for cancer, as increased Hsp90 levels result from the administration of such inhibitors.10 This same HSR is also reponsible for the upregulation of other heat shock proteins, including Hsp70, which exhibit pro-survival activity and can refold protein aggregates that accumulate during the…